08:24 AM EDT, 06/05/2024 (MT Newswires) -- I-Mab ( IMAB ) said Wednesday that it has signed a clinical trial collaboration and supply agreement with Bristol-Myers Squibb ( BMY ) to study the combination of givastomig, an investigational claudin bispecific antibody, to treat patients with advanced claudin 18.2-positive gastric and esophageal cancers.

The collaboration will evaluate the combination of givastomig, with Bristol-Myers' immune checkpoint inhibitor, nivolumab, and chemotherapy, I-Mab ( IMAB ) said.

The study will be conducted by I-Mab ( IMAB ), while Bristol Myers will provide nivolumab, the company said.

Financial terms of the agreement weren't disclosed.

Price: 1.8700, Change: -0.01, Percent Change: -0.53